Iter-4360dd15-0116-transcript
第 116 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 PFS effect size hazard ratio median investigator assessed primary endpoint"})【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0113-transcript", "tags": "iteration transcript", "modified": "20260424215108000", "preview": "!! 第 113 轮执行轨迹 → call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 383108"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹 → call search_memory({"limit":6,"query":"4360dd15 BOLERO-2 hazard ratio median progression-free survival everolimus exemestane 7.8 3.2"})
→ call list_recent({"n":6})
→ call list_tools({})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0109-transcript", "tags": "iteration transcript", "modified": "20260424214407000", "preview": "!! 第 109 轮执行轨迹
→ call search_memory({\"limit\":8,\"query\":\"4360dd15 BOLERO-2 PMID original human trial primary endpoint\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0010-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424175830000\", \"preview\": \"!! 第 10 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":10}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 BOLERO-2 investigator-assessed PFS randomized double-blind phase III accessible source\"}) → call list_recent({\"n\":5}) → call list_tools({}) 【tool:search_memory】【tool:list_recent】
{"ok": true, "items": [{"title": "Error-20260425-055456", "modified": "20260424215456000", "tags": "error iteration"}, {"title": "Iter-4360dd15-0114-reflection", "modified": "20260424215304000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424215304000", "tags": "pinned focus"}, {"title": "先抓可访问摘要再补全文闭环", "modified": "20260424215304000", "tags": "lesson evidence-chain trial-screening metadata-first"}, {"title": "Iter-4360dd15-0114-transcript", "modified": "20260424215258000", "tags": "iteration transcript"}, {"title": "BOLERO-2 可访问非-NEJM 设计/终点证据已补齐", "modified": "20260424215252000", "tags": "fact knowledge 4360dd15 clinical-trials evidence-chain"}]}
【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，//斜体//，[[其它tiddler]]。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 hazard ratio investigator assessed progression free survival result effect size everolimus exemestane"})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0109-transcript", "tags": "iteration transcript", "modified": "20260424214407000", "preview": "!! 第 109 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0114-transcript", "tags": "iteration transcript", "modified": "20260424215258000", "preview": "!! 第 114 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 BOLERO-2 PMID 22149876 primary endpoint trial design accessible authority\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0094-transcr → call web_search({"limit":8,"query":"BOLERO-2 full text pdf progression-free survival everolimus exemestane hazard ratio accessible"})
→ call pubmed_search({"limit":5,"query":"BOLERO-2 everolimus exemestane progression-free survival hazard ratio"})
→ call web_search({"limit":8,"query":"PMCID BOLERO-2 everolimus exemestane pdf"})
→ call web_search({"limit":8,"query":"BOLERO-2 Annals Oncology pdf everolimus exemestane PFS"})
【tool:web_search】
{"ok": true, "query": "BOLERO-2 full text pdf progression-free survival everolimus exemestane hazard ratio accessible", "results": [{"title": "PDF Everolimus Plus Exemestane in Postmenopausal Patients with HR Breast ...", "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "snippet": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Denise A. Yardley • Shinzaburo Noguchi • Kathleen I. Pritchard Michael Gnant • Gabriel N. Hortobagyi • Mario Campone Bohuslav Melichar • Katarina Petrakova • Francis P. Arena Wentao Feng • Ayelet Cahana • Tetiana Taran • David Lebwohl"}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "The BOLERO-2 study showed that the addition of everolimus to exemestane significantly improves progression-free survival , with observed medians of 6.9 and 2.8 months, corresponding to a 57% ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment wi
【tool:pubmed_search】
{"ok": true, "query": "BOLERO-2 everolimus exemestane progression-free survival hazard ratio", "results": [{"pmid": "30679318", "title": "Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.", "source": "Oncologist", "pubdate": "2019 Jul", "authors": ["Prat A", "Brase JC", "Cheng Y", "Nuciforo P", "Paré L", "Pascual T", "Martínez D", "Galván P"], "url": "https://pubmed.ncbi.nlm.nih.gov/30679318/"}, {"pmid": "30092555", "title": "Everolimus-based combination therapies for HR+, HER2- metastatic breast cancer.", "source": "Cancer Treat Rev", "pubdate": "2018 Sep", "authors": ["O'Shaughnessy J", "Thaddeus Beck J", "Royce M"], "url": "https://pubmed.ncbi.nlm.nih.gov/30092555/"}, {"pmid": "27532364", "title": "Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.", "source": "JAMA Oncol", "pubdate": "2016 Oct 1", "authors": ["Chandarlapaty S", "Chen D", "He W", "Sung P", "Samoila A", "You D", "Bhatt T", "Patel P"], "url": "https://pubmed.ncbi.nlm.nih.gov/27532364/"}, {"pmid": "25231953", "title": "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.", "source": "Ann Oncol", "pubdate": "2014 Dec", "authors": ["Piccart M", "Hortobagyi GN", "Campone M", "Pritchard KI", "Lebrun F", "Ito Y", "Noguchi S", "Per
【tool:web_search】
{"ok": true, "query": "PMCID BOLERO-2 everolimus exemestane pdf", "results": [{"title": "238P BOLERO-5: A phase II study of everolimus and exemestane ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(21)02750-2/pdf", "snippet": "The results of the global BOLERO-2 trial established the ef cacy and fi safety of combination everolimus (EVE, an mTOR inhibitor) and exemestane (EXE) in the treatment of ER+, HER2-, locally advanced, recurrent, or metastatic breast cancer (ABC)."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival (PFS) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "PDF Everolimus and exemestane: BOLERO-2 - The Lancet", "url": "https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(11)70376-X.pdf", "snippet": "Everolimus and exemestane : BOLERO-2 In a phase 3 trial, addition of the mTOR inhibitor, everolimus , to an aromatase inhibitor, exemestane , improved progression-free survival (PFS) in postmenopausal patients with hormone-receptor-positive advanced breast cancer."}, {"title": "PDF The BOLERO-2 trial: the addition of everolimus to ex
【tool:web_search】
{"ok": true, "query": "BOLERO-2 Annals Oncology pdf everolimus exemestane PFS", "results": [{"title": "Everolimus plus exemestane for hormone-receptor ... - Annals of Oncology", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival ( PFS ) by more than twofold in patients with hormone-receptor-positive (HR+), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors (NSAIs). The overall survival (OS) analysis is ..."}, {"title": "Everolimus plus exemestane for... : Annals of Oncology", "url": "https://www.ovid.com/journals/anonc/fulltext/10.1093/annonc/mdu456~everolimus-plus-exemestane-for-hormone-receptor-positive", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significantly improved progression-free survival ( PFS ) by more than twofold in patients with hormone-receptor-positive (HR +), HER2-negative advanced breast cancer that recurred or progressed during/after treatment with nonsteroidal aromatase inhibitors ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.sciencedirect.com/science/article/pii/S0923753419369054", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (
→ call web_fetch({"max_chars":7000,"url":"https://pubmed.ncbi.nlm.nih.gov/22149876/"})
→ call web_fetch({"max_chars":7000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3465558/"})
→ call web_fetch({"max_chars":7000,"url":"https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://pubmed.ncbi.nlm.nih.gov/22149876/'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3465558/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Membrane Fission Is Promoted by Insertion of Amphipathic Helices and Is Restricted by Crescent BAR Domains - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Cell . 2012 Mar 30;149(1):124–136. doi: 10.1016/j.cell.2012.01.047 Search in PMC Search in PubMed View in NLM Catalog Add to search Membrane Fission Is Promoted by Insertion of Amphipathic Helices and Is Restricted by Crescent BAR Domains Emmanuel Boucrot Emmanuel Boucrot 1 MRC Laboratory of Molecular Biology, Hills Road, Ca
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/content/pdf/10.1007/s12325-013-0060-1.pdf", "status": 200, "content_type": "application/pdf", "text": "%PDF-1.4\r%����\r\n231 0 obj\r<</Linearized 1/L 517515/O 234/E 194693/N 15/T 512774/H [ 2096 1101]>>\rendobj\r \r\nxref\r\n231 90\r\n0000000016 00000 n\r\n0000003197 00000 n\r\n0000003365 00000 n\r\n0000003401 00000 n\r\n0000003956 00000 n\r\n0000004119 00000 n\r\n0000005064 00000 n\r\n0000006229 00000 n\r\n0000006401 00000 n\r\n0000007567 00000 n\r\n0000008469 00000 n\r\n0000008633 00000 n\r\n0000008736 00000 n\r\n0000008773 00000 n\r\n0000009651 00000 n\r\n0000009790 00000 n\r\n0000010428 00000 n\r\n0000011330 00000 n\r\n0000012497 00000 n\r\n0000013664 00000 n\r\n0000013720 00000 n\r\n0000027228 00000 n\r\n0000028549 00000 n\r\n0000029249 00000 n\r\n0000029888 00000 n\r\n0000031054 00000 n\r\n0000032166 00000 n\r\n0000032329 00000 n\r\n0000032470 00000 n\r\n0000033290 00000 n\r\n0000045052 00000 n\r\n0000045106 00000 n\r\n0000046158 00000 n\r\n0000046795 00000 n\r\n0000047960 00000 n\r\n0000048041 00000 n\r\n0000048462 00000 n\r\n0000049433 00000 n\r\n0000049472 00000 n\r\n0000050019 00000 n\r\n0000050153 00000 n\r\n0000093441 00000 n\r\n0000093741 00000 n\r\n0000093794 00000 n\r\n0000093895 00000 n\r\n0000094127 00000 n\r\n0000095139 00000 n\r\n0000096303 00000 n\r\n0000097203 00000 n\r\n0000098030 00000 n\r\n0000098857 00000 n\r\n0000108317 00000 n\r\n0000109273 00000 n\r\n0000111966 00000 n\r\n0000115264 00000 n\r
→ call web_search({"limit":10,"query":"\"BOLERO-2\" \"final progression-free survival analysis\" hazard ratio median 7.8 3.2"})
→ call web_search({"limit":10,"query":"\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" hazard ratio"})
→ call web_search({"limit":10,"query":"\"BOLERO-2\" \"hazard ratio\" \"progression-free survival\" everolimus exemestane 7.8 3.2"})
【tool:web_search】
{"ok": true, "query": "\"BOLERO-2\" \"final progression-free survival analysis\" hazard ratio median 7.8 3.2", "results": [{"title": "Abstract P6-04-02: Final progression-free survival analysis of BOLERO-2 ...", "url": "https://aacrjournals.org/cancerres/article/72/24_Supplement/P6-04-02/576954/Abstract-P6-04-02-Final-progression-free-survival", "snippet": "Interim analyses of the BOLERO-2 trial demonstrated that combining the oral mammalian target of rapamycin (mTOR) inhibitor, everolimus (EVE), with the steroidal aromatase inhibitor, exemestane (EXE), significantly prolonged progression-free survival (PFS) in this patient population. Protocol-specified final PFS analyses are presented."}]}
【tool:web_search】
{"ok": true, "query": "\"Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis\" hazard ratio", "results": [{"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR", "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "snippet": "Kaplan-Meier estimates of progression-free survival of patients treated with everolimus plus exemestane versus exemestane alone based on assessment by a local investigator or b central review. CI confidence interval, HR hazard ratio , EVE everolimus, EXE exemestane, PBO placebo"}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast ...", "url": "https://escholarship.org/uc/item/0715f3jd", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR (+) advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall ..."}, {"title": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast ...", "url": "https://www.springermedicine.com/everolimus-plus-exemestane-in-postmenopausal-patients-with-hr-br/23097536", "snippet": "Methods BOLERO-2 is a phase 3, double-blind, randomized, international trial comparing everolimus (10 mg/day) p
【tool:web_search】
{"ok": true, "query": "\"BOLERO-2\" \"hazard ratio\" \"progression-free survival\" everolimus exemestane 7.8 3.2", "results": []}
→ call web_fetch({"max_chars":7000,"url":"https://escholarship.org/uc/item/0715f3jd"})
→ call web_fetch({"max_chars":7000,"url":"https://link.springer.com/article/10.1007/s12325-013-0060-1"})
→ call web_fetch({"max_chars":7000,"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1109653"})
【tool:web_fetch】
{"ok": true, "url": "https://escholarship.org/uc/item/0715f3jd", "status": 202, "content_type": "text/html; charset=UTF-8", "text": "", "truncated": false}
【tool:web_fetch】
{"ok": true, "url": "https://link.springer.com/article/10.1007/s12325-013-0060-1", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis | Advances in Therapy | Springer Nature Link Skip to main content Advertisement Log in Menu Find a journal Publish with us Track your research Search Saved research Cart Home Advances in Therapy Article Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Original Research Open access Published: 25 October 2013 Volume 30 , pages 870–884, ( 2013 ) Cite this article You have full access to this open access article Download PDF Save article View saved research Advances in Therapy Aims and scope Submit manuscript Everolimus Plus Exemestane in Postmenopausal Patients with HR + Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis Download PDF Denise A. Yardley 1 , Shinzaburo Noguchi 2 , Kathleen I. Pritchard 3 , Howard A. Burris III 1 , José Baselga 4 , Michael Gnant 5 , Gabriel N. Hortobagyi 6 , Mario Campone 7 , Barbara Pistilli 8 , Martine Piccart 9 , Bohuslav Melichar 10 , Katarina Petrakova 11 , Francis P. Arena 12 , Frans Erdkamp 13 , Wael A. Harb 14 , Wentao Feng 15 , Ayelet Cahana 15 , Tetiana Taran 15 , David Lebwohl 15 & … Hope S. Rugo 16 Show authors 24k Accesses 492 Citations 41 Altmetric 2 Mentions Explore al
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://www.nejm.org/doi/full/10.1056/NEJMoa1109653'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
→ call write_note({"tags":["fact","knowledge","4360dd15","clinical-trials","evidence-chain"],"text":"!! BOLERO-2 主要终点的具体结果数值（可访问权威全文）\n''结论'' 在可访问的 Springer Open Access 全文中，BOLERO-2 的主要终点（primary endpoint）= ''local investigator review 的 PFS''，最终分析结果为：\n\n- investigator review: median PFS ''7.8 vs 3.2 months''；''hazard ratio 0.45''（95% CI 0.38–0.54）；log-rank P < 0.0001\n- central review: median PFS ''11.0 vs 4.1 mon)
【tool:write_note】
{"ok": true, "path": "C:\\Users\\yh599\\Documents\\GitHub\\LLM-yh\\Sisyphus\\wiki\\tiddlers\\BOLERO-2_主要终点具体结果数值_Springer_OA.tid", "title": "BOLERO-2 主要终点具体结果数值（Springer OA）"}
【assistant】
已完成本轮：找到并提取了 BOLERO-2 主要终点的具体效应量。
关键信息：
- 主要终点：local investigator review 的 PFS
- 最终分析结果：
- 7.8 vs 3.2 months
- HR 0.45（95% CI 0.38–0.54）
- P < 0.0001
- 独立 central review：
- 11.0 vs 4.1 months
- HR 0.38（95% CI 0.31–0.48）
- P < 0.0001
我已经把这条结果写入长期记忆，作为可复现的知识条目。
下一轮最值得做的最窄子问题是：把 BOLERO-2 的 overall survival 结果与主要毒性事件提取出来，量化“获益—风险”比。
<NEXT_FOCUS>提取 BOLERO-2 的 overall survival 结果与最常见 3–5 个 ≥3 级不良事件，量化获益—风险比。</NEXT_FOCUS>